TRCT
CSTL icon

Tower Research Capital (TRC)’s Castle Biosciences CSTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.1K Buy
2,773
+1,169
+73% +$26K ﹤0.01% 2528
2026
Q1 		$39.4K Sell
1,604
-409
-20% -$13.4K ﹤0.01% 2957
2025
Q4 		$78.3K Sell
2,013
-1,653
-45% -$53.3K ﹤0.01% 2117
2025
Q3 		$83.5K Buy
3,666
+875
+31% +$17.8K ﹤0.01% 2146
2025
Q2 		$57K Buy
2,791
+2,009
+257% +$37.2K ﹤0.01% 2854
2025
Q1 		$15.7K Sell
782
-10,483
-93% -$260K ﹤0.01% 3209
2024
Q4 		$300K Buy
11,265
+7,524
+201% +$229K 0.01% 1411
2024
Q3 		$107K Sell
3,741
-205
-5% -$5.22K ﹤0.01% 2178
2024
Q2 		$85.9K Buy
3,946
+3,756
+1,977% +$83.7K ﹤0.01% 2684
2024
Q1 		$4.21K Sell
190
-5,153
-96% -$112K ﹤0.01% 4714
2023
Q4 		$115K Buy
5,343
+4,366
+447% +$76.8K ﹤0.01% 2541
2023
Q3 		$16.5K Sell
977
-10
-1% -$175 ﹤0.01% 3555
2023
Q2 		$13.5K Buy
987
+362
+58% +$7.33K ﹤0.01% 3758
2023
Q1 		$14K Buy
625
+160
+34% +$3.91K ﹤0.01% 3873
2022
Q4 		$11K Sell
465
-1,356
-74% -$31.4K ﹤0.01% 3800
2022
Q3 		$47K Buy
1,821
+691
+61% +$19.4K ﹤0.01% 3210
2022
Q2 		$25K Sell
1,130
-1,713
-60% -$39.8K ﹤0.01% 3549
2022
Q1 		$128K Buy
2,843
+2,400
+542% +$99.2K ﹤0.01% 2029
2021
Q4 		$19K Sell
443
-2,236
-83% -$117K ﹤0.01% 3709
2021
Q3 		$178K Sell
2,679
-1,769
-40% -$124K ﹤0.01% 1921
2021
Q2 		$326K Buy
4,448
+606
+16% +$40K 0.01% 1528
2021
Q1 		$263K Sell
3,842
-5,016
-57% -$377K ﹤0.01% 1774
2020
Q4 		$595K Buy
8,858
+455
+5% +$24.7K 0.02% 867
2020
Q3 		$432K Buy
8,403
+6,295
+299% +$280K ﹤0.01% 1844
2020
Q2 		$79K Buy
+2,108
New +$72K ﹤0.01% 2654
2020
Q1 		– Sell
-2,476
Closed -$85K – 3168
2019
Q4 		$85K Buy
+2,476
New +$60.5K 0.01% 1033

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s CSTL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Castle Biosciences (CSTL) stake by 73% in Q2 2026, buying an estimated $26K and bringing the position to 2,773 shares worth $66.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

Tower Research Capital (TRC) first reported a position in CSTL in Q4 2019 and has held it in 26 quarters since. The position peaked at $595K in Q4 2020. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Tower Research Capital (TRC) held 2,773 shares of Castle Biosciences worth $66.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,169 Castle Biosciences shares in Q2 2026, an estimated $26K.
  • Castle Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2528 holding.
  • Tower Research Capital (TRC) first reported a position in Castle Biosciences in Q4 2019 and has held it in 26 quarters since.
  • Tower Research Capital (TRC)'s Castle Biosciences position peaked at $595K in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.